(800) 424-6690

Submit Your Information for the
Rocket Pharmaceuticals Lawsuit

Lead plaintiff deadline is August 11, 2025.

If you purchased or acquired Rocket Pharmaceuticals securities between September 17, 2024 and May 26, 2025, please contact Berger Montague using the form below.

First Name

Last Name

Email

Phone Number

Address

City

Zip

State

Are you a current or former employee of Rocket Pharmaceuticals?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

Terms of Use *

I agree to the terms of service

Subscribe

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

Please view our terms of use policy and our privacy policy.

About the Rocket Pharmaceuticals Lawsuit

The case was filed in the U.S. District Court for the District of New Jersey and alleges that Rocket Pharmaceuticals misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program.

The lawsuit alleges that the Company failed to inform investors of a substantial protocol change, specifically the addition of a novel immunomodulatory agent, prior to a serious adverse event (SAE) and subsequent FDA clinical hold. Following the Company’s disclosure of a patient death in the trial, RCKT shares fell nearly 37%, from $6.27 on May 23, 2025, to $2.33 on May 27, 2025.

Investors who purchased or acquired Rocket Pharmaceuticals securities between September 17, 2024 and May 26, 2025, may no later than August 11, 2025, seek to be appointed as a lead plaintiff representative of the class.